Form 4: Janux Therapeutics CSO Thomas DiRaimondo Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Thomas DiRaimondo, Chief Scientific Officer of Janux Therapeutics, sold a portion of his holdings in the company's common stock on September 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 27, 2024, Thomas DiRaimondo, the Chief Scientific Officer of Janux Therapeutics, sold shares of the company's common stock.
- The sales were executed under a Rule 10b5-1 trading plan adopted on June 28, 2024.
- A total of 4,325 shares were sold at a weighted average price of $46.2057, with prices ranging from $45.70 to $46.69.
- An additional 675 shares were sold at a weighted average price of $47.2245, with prices ranging from $46.79 to $47.77.
- Following these transactions, DiRaimondo directly owns 97,938 shares of Janux Therapeutics common stock.
- This total includes 1,406 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2024.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions.
Industry Context
Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information.
Stakeholder Impact
- The stock sale by a key executive could be perceived negatively by some investors, potentially leading to short-term price fluctuations.
- However, the existence of a 10b5-1 plan mitigates concerns about opportunistic trading based on inside information.
Key Dates
| Date | Description |
|---|---|
| 2024-05-15 | Reporting person acquired 1,406 shares under the Issuer's 2021 Employee Stock Purchase Plan |
| 2024-06-28 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-09-27 | Date of stock sale transactions |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.